John D Grainger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8438379/publications.pdf

Version: 2024-02-01

41 papers

3,490 citations

567281 15 h-index 395702 33 g-index

41 all docs

41 docs citations

41 times ranked

2795 citing authors

#	Article	IF	CITATIONS
1	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (<scp>ERCI</scp>) network. British Journal of Haematology, 2022, 197, 633-638.	2.5	2
2	A Single-Arm, Long-Term Efficacy and Safety Study of Subcutaneous Romiplostim in Children with Immune Thrombocytopenia. Blood Advances, 2022, , .	5.2	1
3	Real-world experience with caplacizumab in the management of acute TTP. Blood, 2021, 137, 1731-1740.	1.4	93
4	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. Acta Haematologica, 2021, 144, 418-426.	1.4	17
5	UK second-line paediatric primary ITP therapy analysis. Archives of Disease in Childhood, 2021, 106, 929.1-931.	1.9	1
6	Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. Annals of Hematology, 2021, 100, 2143-2154.	1.8	7
7	Adolescents and Young Adults with Immune Thrombocytopenia (ITP): A Project of the Carmen-France and Parc-ITP Registry. Blood, 2021, 138, 2079-2079.	1.4	1
8	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	2.2	10
9	COVIDâ€19 – Impact on Childhood Haematology Patients. HemaSphere, 2020, 4, e465.	2.7	9
10	Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials. Pediatric Blood and Cancer, 2020, 67, e28630.	1.5	6
11	Practical guidance for the management of adults with immune thrombocytopenia during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 189, 1038-1043.	2.5	89
12	Impact of prophylaxis on healthâ€related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 397-404.	2.3	12
13	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	5.2	593
14	Healthâ€related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. British Journal of Haematology, 2019, 185, 102-106.	2.5	15
15	The prevention of glucocorticoidâ€induced osteoporosis in patients with immune thrombocytopenia receiving steroids: aÂBritish Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 410-417.	2.5	10
16	Updated Results from the Single-Arm, Open-Label, Long-Term Efficacy and Safety Study of Subcutaneous (SC) Romiplostim in Children with Immune Thrombocytopenia (ITP). Blood, 2019, 134, 1095-1095.	1.4	6
17	A comparative prospective observational study of children and adults with immune thrombocytopenia: 2â€year followâ€up. American Journal of Hematology, 2018, 93, 751-759.	4.1	38
18	<scp>BSH</scp> Guideline: management of thrombotic and haemostatic issues in paediatric malignancy. British Journal of Haematology, 2018, 180, 511-525.	2.5	15

#	Article	IF	Citations
19	A United Kingdom Immune Thrombocytopenia (<scp>ITP</scp>) Forum review of practice: thrombopoietin receptor agonists. British Journal of Haematology, 2018, 180, 591-594.	2.5	7
20	How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. British Journal of Haematology, 2018, 182, 621-632.	2.5	71
21	Safety and Efficacy of Romiplostim in over 200 Children with Immune Thrombocytopenia (ITP): Results of an Integrated Database of 5 Clinical Trials. Blood, 2018, 132, 2428-2428.	1.4	2
22	A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia. Pediatric Hematology and Oncology, 2017, 34, 73-89.	0.8	11
23	Guidelines on the management of drugâ€induced immune and secondary autoimmune, haemolytic anaemia. British Journal of Haematology, 2017, 177, 208-220.	2.5	93
24	The diagnosis and management of primary autoimmune haemolytic anaemia. British Journal of Haematology, 2017, 176, 395-411.	2.5	164
25	Eltrombopag for chronic immune thrombocytopenia – Authors' reply. Lancet, The, 2016, 387, 336-337.	13.7	0
26	Response to First Line Treatment in Childhood ITP. Blood, 2016, 128, 1372-1372.	1.4	3
27	United Kingdom Experience of Intracranial Bleeds in Childhood Immune Thrombocytopenia. Blood, 2016, 128, 1380-1380.	1.4	2
28	Management of Activity in Immune Thrombocytopenia, Fat or Fit?. Pediatric Blood and Cancer, 2015, 62, 2069-2070.	1.5	0
29	Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2015, 386, 1649-1658.	13.7	164
30	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematology,the, 2015, 2, e315-e325.	4.6	146
31	Second Line ITP Therapy in the UK: Results from the UK Paediatric ITP Registry. Blood, 2015, 126, 3478-3478.	1.4	0
32	PETIT and PETIT 2: Treatment with Eltrombopag in 171 Children with Chronic Immune Thrombocytopenia (ITP). Blood, 2014, 124, 1450-1450.	1.4	7
33	Thrombopoietin Receptor Agonists in Paediatric ITP Patients: Long Term Follow up Data in 34 Patients. Blood, 2014, 124, 4206-4206.	1.4	6
34	Quality of life in immune thrombocytopenia following treatment. Archives of Disease in Childhood, 2013, 98, 895-897.	1.9	17
35	Quality of life in childhood immune thrombocytopenia: International validation of the kids' ITP tools. Pediatric Blood and Cancer, 2013, 60, 95-100.	1.5	33
36	Changing trends in the UK management of childhood ITP. Archives of Disease in Childhood, 2012, 97, 8-11.	1.9	34

#	Article	IF	CITATIONS
37	Outcome of Treatment Episodes in UK Children with ITP. Blood, 2012, 120, 3334-3334.	1.4	O
38	International consensus report on the investigation and management of primary immune thrombocytopenia. Blood, 2010, 115, 168-186.	1.4	1,802
39	Retrospective Review of Life-Threatening Bleeds in Paediatric ITP Blood, 2009, 114, 4453-4453.	1.4	0
40	Changing Trends in ITP Management from 1995 to 2007: An Interim Report from the UK Paediatric ITP Registry Blood, 2008, 112, 3411-3411.	1.4	0
41	Cultured autografting for juvenile myelomonocytic leukaemia. British Journal of Haematology, 2002, 117, 477-479.	2.5	3